PRZOOM - /newswire/ -
Raleigh, NC, United States, 2013/04/23 - Benefits of new proprietary SUBA technology include improved and consistent drug absorption, reducing patient variability and, potentially, side effects - MetricsInc.com.
Metrics, Inc. is offering a new proprietary technology (SUBA™) that enhances the bioavailability of poorly water-soluble drugs.
A solid dispersion is formed between the drug and specific pharmaceutically acceptable polymers. The dispersions, in powder form, are delivered to the body via hard gelatin capsules or tablets. Once in the small intestine, the drug-polymer combination changes form, presenting the drug in a way that is much more rapidly absorbed through the intestinal wall compared to standard crystalline forms of the drug.
“The small intestine absorbs certain active pharmaceutical ingredients including those that are poorly water soluble more readily than does the stomach,” said Dr. Brad Gold, vice president of pharmaceutical development. “SUBA technology takes advantage of the body’s natural digestive processes to deliver a poorly water-soluble active ingredient to the place where it can do the most good.”
Potential benefits of SUBA technology include fewer side effects for patients and reduced intra- and inter-patient variability, Gold added,“which is especially important when pharmaceutical companies are studying new drug therapies in clinical trials.”
Metrics Inc. (metricsinc.com) is a full-service global pharmaceutical development and manufacturing organization serving clients worldwide. The addition of SUBA technology to Metrics’ portfolio of formulation and manufacturing capabilities is the result of its recent acquisition by Mayne Pharma Group Limited.
Mayne Pharma has successfully applied SUBA technology to improve the bioavailability of the poorly soluble and highly variable anti-fungal drug itraconazole, and has recently received regulatory approval to market this significantly improved formulation of itraconazole (brand name Lozanoc®) in a number of European markets.
Together, Metrics and Mayne offer an impressive proprietary portfolio of advanced drug delivery technologies for controlled release, bioavailability enhancement and taste masking. By collaborating with partners, the companies can develop and distribute novel prescription and over-the-counter products that offer advantages over existing products and meet unmet medical needs. Applied appropriately, these technologies can deliver therapeutic or convenience benefits to patients, including a reduced dosing frequency, increased compliance, improved side effect profile and a more constant therapeutic effect.
Metrics’ areas of expertise include quality pharmaceutical formulation development; first-time-in-man (FTIM) formulations; clinical trial manufacturing (CTM) for Phase I, II and III trials; and analytical method development and validation services leading to commercial scale manufacturing.
Headquartered in Greenville, N.C., Metrics proudly operates as a subsidiary of Mayne Pharma.